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Abstract 
 
Preoperative anaemia and perioperative red blood cell transfusions carry significant consequence when 
it comes to surgical outcomes.  Establishment of patient-centred clinical pathways have been designed 
to harness and endorse good transfusion practice termed the three pillars of patient blood management 
(PBM). These focus on the timely and appropriate management of anaemia, prevention of blood loss 
and restrictive transfusion where appropriate. This article reviews the current evidence and ongoing 
research in the field of PBM in surgery. Strategies to implement PBM have shown significant benefits 
in appropriate transfusion practice, reduced costs and improved patient length of hospital stay. Recently 
published national quality standards have recognised the importance of  the PBM blueprint in surgery 
considering alternatives to red blood cell transfusion, active measures to reduce perioperative blood loss 
and the appropriate management of postoperative anaemia.  Adopting PBM in surgical patients, should 
be paramount to reduce the risks posed by perioperative anaemia and blood transfusions.  Principles of 
PBM help structure the interventions and decisions relating to anaemia and blood transfusion, but more 
importantly represent a paradigm shift towards a more considered approach to blood transfusion, 
acknowledging its risks, preventatives and alternatives. 
 
 
Why is Pre-Operative Anaemia a Problem? 
 
Pre-operative anaemia carries patient consequence when it comes to surgical outcomes.  In the hospital 
setting, a third of elective surgical patients are admitted with coexisting anaemia, which alone is an 
established risk factor for a number of adverse outcomes.  Whilst anaemia increases need for red blood 
cell (RBC) transfusion, anaemia is associated with increased patient morbidity and mortality correlating 
with the degree of anaemia.  
In the last few years there has been a stepwise increment in the quantity of publications, revealing good 
quality evidence of the independent association with worse outcome in patients who have preoperative 
anaemia across most surgical specialties, including orthopaedics, upper/lower GI, hepatobiliary, and 
gynaecology (Carson et al, 1996; Mussallam et al, 2011; Jans et al, 2013; Baron et al, 2014; Fowler et 
al, 2015).    Prevalence of preoperative anaemia in the surgical population, when both genders are 
incorporated, sits at approximately 30% (Munoz et al, 2011).  In a secondary analysis of 39 309 patients 
undergoing non-cardiac surgery in the European Surgical Outcomes Study (EuSOS), multivariable 
analysis showed that patients with severe or moderate anaemia had a higher in-hospital mortality than 
those with normal preoperative haemoglobin concentration: OR 2.28 (95% CI; 2.06 to 3.85) and 1.99 
(95% CI; 1.67 to 2.37), respectively (Ferraris et al, 2012).  
Preoperative anaemia is the strongest indicator for perioperative blood transfusion.  The emphasis 
placed on recognising at risk patients and managing accordingly is supported by the association of 
anaesthetists of Great Britain and Ireland (AAGBI, 2016), NHS Blood and Transplant (NHSBT, 2013), 
British Society of Haematology (BSH; Kotzé et al, 2015) and National Institute for Health and Care 
Excellence (NICE; NICE Guideline 24, 2015).  However, the current standard of care for anaemic 
patients during surgical admission is management by a RBC transfusion.   
Establishment of patient-centred clinical pathways have been designed to harness and endorse good 
transfusion practice; termed the three pillars of patient blood management (PBM).  These focus on the 
timely and appropriate management of anaemia, prevention of blood loss and restrictive transfusion 
where appropriate.  In the setting of surgery, these three pillars of PBM align with preoperative, 
operative and post-operative care.  Many centres globally, including those in Australia, Europe and the 
US have championed the PBM initiative, albeit with expected apprehension amongst clinicians.  This 
is due to the overriding issues of hospital culture challenging new strategies, and the reluctance to 
implement PBM bundles due to the limited amount of evidence on whether these interventions do have 
a positive impact in patient outcome.  This review focuses on the current evidence for practical 
implementation and safety of the PBM pillars in surgery and ongoing research in the field.   
  
Patient blood management in Surgery 
 
Table 1. Implementing PBM in elective surgery. 
Pillar 1. Anaemia Management 
Pre-operative Intra-operative Post-operative 
 Diagnosis of anaemia 
(Ideally two weeks prior to 
planned surgery) 
 Identification of underlying 
cause of anaemia: Perform 
Full Blood Count (FBC) 
o Performed by GP as 
apart of referral 
process OR initial 
surgical outpatients 
o Educate 
surgical/perioperative 
teams which 
procedures are most 
likely to require 
anaemia screening 
e.g. major open 
abdominal surgery 
 Diagnosis of IDA, 
B12/Folate deficiency 
 Extended diagnosis of 
anaemia e.g. further referral 
to gastroenterology, 
endoscopy, haematology 
 Treatment of anaemia 
o IV Iron, B12/Folate, 
EPO 
 
 Optimising 
cardiovascular and 
pulmonary tolerance 
 Haemodynamic 
monitoring in high-risk 
procedures/patients 
 Manage post-operative 
anaemia (whether developed 
as consequence of surgery 
or pre-existing) 
o IV Iron/EPO 
o Avoidance of 
unnecessary ‘top-
up’ transfusions. 
Pillar 2. Managing Perioperative Bleeding 
Pre-operative Intra-operative Post-operative 
 Identifying at-risk patients 
(surgical outpatients/pre-
operative assessment) 
o Including full 
medical and 
pharmaceutical 
review 
 Ensuring physiological 
management and 
optimal conditions for 
haemostasis (e.g. 
normothermia, pH 
>7.2) 
 Point-of-care testing 
(e.g. viscoelastic 
methods) 
 Cell salvage 
 Surgical technique 
 
 Monitor and manage 
ongoing bleeding e.g. cell 
salvage 
 Maintain physiological 
conditions 
 Minimise unnecessary 
phlebotomy 
 Haemostasis/anticoagulation 
management 
Pillar 3. Managing Post-Operative Anaemia 
Pre-operative Intra-operative Post-operative 
 Patient-focused care – 
identifying and optimising 
patient’s physiological 
reserve 
 Cell salvage  Evidence-based transfusion 
thresholds 
 Manage IDA with IV Iron 
 
Patient blood management is a globally recognised and WHO-endorsed concept (WHA63.12) that aims 
to manage the issues of pre-operative anaemia and blood transfusion by addressing quality and safety 
of transfusion practice.  Strategies to implement PBM have shown significant benefits in appropriate 
transfusion practice, reduced costs and improved patient length of stay (Moskowitz et al, 2010; 
Theusinger et al, 2014; Goodnough, 2014; Gross et al, 2-15; Meybohm et al, 2016). This was best 
highlighted in the summary report from the Western Australian PBM initiative; a six-year educational 
jurisdiction wide program of PBM introduction was associated with a reduction in preoperative anaemia 
rates, reduced blood transfusion and overall blood product utilisation with associated reduction in length 
of hospital stay and improved patient outcomes (Leahy et al, 2017).   
 
PBM guidelines and standards have developed from Australian lead professional associations. 
Providing detailed evidence-based information and recommendations on PBM in Australia, USA, and 
in several European nations (Kozek-Langenecker et al, 2013; Society for Advancement of Blood 
Management, 2013; Joint UK Blood Transfusion and Tissue Transplantation Services, 2014; American 
Society of Anesthesiologists, 2015; Hunt et al, 2015; Klein et al, 2016).  A recent paper by Meybohm 
and colleagues, provided comprehensive bundles of PBM components encompassing more than 100 
different PBM measures to facilitate a stepwise implementation process of the most feasible measures 
(Meybohm et al, 2017).  Practical recommendations targeting elective surgery have been summarised 
in Table 1 and will be expanded further in this review.  
Recently published NICE quality standards for blood transfusion have also incorporated many features 
of the PBM blueprint including consideration of alternatives to blood transfusion, active measures to 
reduce perioperative blood loss and the appropriate management of postoperative anaemia (Table 2) 
(NICE, 2016). 
Table 2. NICE Quality Standards (NICE, 2016). 
Standards  
Statement 1 People with iron-deficiency anaemia who are having surgery are offered iron 
supplementation before and after surgery. 
Statement 2 Adults who are having surgery and expected to have moderate blood loss are 
offered tranexamic acid. 
Statement 3 People are clinically reassessed and have their haemoglobin levels checked 
after each unit of red blood cells they receive, unless they are bleeding or are 
on a chronic transfusion programme. 
Statement 4 People who may need or who have had a transfusion are given verbal and 
written information about blood transfusion. 
 
Pillar 1 – Managing Pre-Operative Anaemia in the Surgical Patient 
 
Despite multiple guidelines and opinion documents on the management of pre-operative anaemia, or 
mandates such as those developed by NICE few provide pragmatic guidance or strong evidence-based 
platforms for the underlying determinant of anaemia in surgical patients.   
The cause of anaemia in the pre-operative patient can often be complex and multifactorial.  Nutritional 
deficiencies (e.g. Iron, B12, Folate) and chronic inflammatory states are the major contributors. The 
issue for diagnosis of iron deficiency anaemia (IDA) is inconsistency in the awareness and education 
surrounding the mechanisms of ID in surgical patients. Also, the absence of clear pathways and clinics 
in place to assist the diagnosis and treatment.   
It is recommended that in elective surgical patients undergoing a major surgical procedure, with an 
expected blood loss >500mls or a high probability of requiring a RBC transfusion, they have a full 
blood count (FBC), that is reviewed, at least two weeks prior to surgery (Muñoz et al, 2017).  If a patient 
is found to have unexpected pre-operative anaemia or suboptimal haemoglobin (Hb), surgery should be 
delayed in the setting of elective major procedures (characteristically for arthroplasty surgery) until 
satisfactory review and management is completed (Goodnough et al, 2011).  Additionally, screening 
for common nutritional deficiencies; ferritin, B12 and folate should be standard practice, in order to 
direct care and achieve patient optimisation appropriately.  Several diagnostic algorithms have been 
published with regards to this (Muñoz et al, 2017; Goodnough and Schrier, 2014). Unfortunately, these 
recommendations have been faced with many hurdles, often revealing the disengagement between 
primary and tertiary healthcare.  In addition, many centres have emphasised the need to fast-track 
patients and provide same-day admission, contradicting the PBM principles of pre-operative patient 
optimisation.  Surgical trials focusing on this aspect of PBM are ongoing with aim to provide more 
evidence surrounding the effectiveness of pre-operative anaemia management (Richards et al, 2015; 
Spahn et al, 2016; Bemelman et al, 2016).   
 
Treatment strategies for Iron Deficiency Anaemia 
 
The proposed treatment of pre-operative IDA in surgical patients with IV iron, has been of particular 
focus over the past few years as an approach to managing what we now recognise as an often complex, 
multifactorial condition.   
The British Society of Gastroenterology and NICE guidance for the management of pre-operative IDA 
state that all patients should have iron supplementation to correct anaemia and replenish body stores, 
and the option of parenteral iron should be considered when oral preparations are not tolerated or 
ineffective (NICE, 2015; Ponikowski et al, 2015).  Although, this may be effective to raise the [hb] in 
this setting there remains a significant paucity in the evidence as to whether using intravenous iron in 
the preoperative setting has any patient benefit and equipoise remains. 
Oral iron remains the first-line, low-cost recommendation for IDA.  Total body stores of iron are 3000-
4000mg in healthy humans with a normal turnover / loss of 2mg per day.  A systematic review has 
demonstrated that oral iron may reduce the proportion of patients requiring blood transfusion (Goddard 
et al, 2011).  However, enteral iron is absorbed at a rate of 2-16mg per day, and 3-6 months of treatment 
can be required to provide 1000-2000mg to replenish the physiological reserve of iron as the 
bioavailability of ferrous iron is only 10-15%.  This is further reduced by poor absorption resulting from 
downregulation of duodenal absorption by inflammation, infection and chronic disease.  Reduced 
uptake is one of the main reasons why oral iron may often fail to ameliorate anaemia in the surgical 
cohort.  Further, compliance can also be poor owing to the common side-effects associated with oral 
iron salts, including abdominal pain, diarrhoea and constipation.  Meta-analysis has shown oral iron 
salts have an OR of 2.32 (95% CI; 1.74 to 3.08; P < 0.001) compared with placebo for gastrointestinal 
side effects (Clevenger et al, 2016). 
 
Intravenous iron, has been demonstrated as an alternative treatment for correcting IDA in surgical 
patients.  Several intravenous iron preparations are available, including iron polymaltose, ferumoxytol, 
ferric carboxymaltose, iron sucrose, and iron isomaltoside (Tolkien et al, 2015).  Historically, parenteral 
iron preparations were associated with high rates of adverse effects including anaphylaxis, but these 
reactions were related to historical dextran-containing preparations.  Modern carbohydrate preparations 
have a significantly improved safety profile with an overall anaphylaxis rate comparable to that for IV 
penicillin (Wang et al, 2015), about 3-10 per 100,000. Overall the sever adverse event rate for modern 
IV irons is about 3-4 times less than for a unit of blood. There is good evidence for their safety and 
efficacy in a range of conditions, including the perioperative setting (Auerbach et al, 2013).   
A systematic review involving patients with anaemia undergoing surgery (including orthopaedics, 
colorectal, gynaecology, spinal, cardiac, upper GI and head and neck) demonstrated an increase in 
haemoglobin concentration and reduced risk of RBC transfusion (relative risk (RR) 0.74, 95% CI; 0.62 
to 0.88) with intravenous iron, especially when used with erythropoiesis stimulating agents (ESAs) or 
in patients with lower ferritin concentrations, without significant difference in mortality or serious 
adverse events (Lin et al, 2017).   
Two recent surgical trials involving the use of IV iron to treat preoperative anaemia in patients 
undergoing colorectal and unspecified abdominal surgery, have shown conflicting responses in terms 
of transfusion outcomes (Froessler et al, 2016; Keeler et al, 2017).  A trial by Froessler and colleagues 
show a significant reduction in RBC transfusion use by 60% in patients treated with IV iron pre-
operatively (Froessler et al, 2016).  No difference was observed in secondary outcomes in terms of 
morbidity, mortality and quality of life, likely due to small recruitment size.  The study by Keeler and 
authors, showed that IV iron while more effective in increasing Hb compared to oral iron, made no 
difference in terms of RBC transfusion use for colorectal surgery patients (Keeler et al, 2017).  Both 
trials, small in population, have only identified primary outcomes in terms of RBC transfusion use, 
indicating that need for the continuation of larger ongoing trials and development of new studies 
investigating more insightful primary patient outcomes with focus on functional performance and 
quality of life (Richards et al, 2015; Spahn et al, 2016; Bemelman et al, 2016). 
 
Pillar 2 - Management of Intraoperative Bleeding 
 
Risk stratification of the surgical patient is important.  Bleeding history must be included as part of the 
preoperative assessment, including a medication review, focusing on the use of anticoagulants.  
Intraoperative bleeding may be impacted by surgical techniques, anaesthetic blood loss reduction 
strategies e.g. point of care and cell salvage, and pharmacological management. 
 
The key factor in current practices is the increasing numbers of patients continued on anticoagulants 
and antiplatelets well into the perioperative period.  Annually, approximately 10% of patients on any 
long-term oral anticoagulation will undergo surgery or other invasive procedure (Douketis et al, 2012).  
Anticoagulants are commonly prescribed agents for the prevention and treatment of a number of 
cardiovascular conditions.  The BRIDGE study showed that patients on warfarin undergoing elective 
invasive procedure, foregoing bridging anticoagulation, faired no different in terms of reducing arterial 
thromboembolism and demonstrated reduced bleeding risk (Douketis et al, 2015).    
 
Point of care testing 
 
The guided management of coagulopathy through the use of point of care testing has shown to be a 
valuable tool.  Unlike the conventional means of coagulation analysis, which is prolonged and often 
inaccurate, the development of viscoelastic testing (this allows changes of a blood clots tensile strength 
to be measured over time) now provides real time and rapid analysis of the dynamics of clot formation. 
In recent years, an increase in the worldwide use of viscoelastic testing such as thromboelastography 
(TEG®) and rotational thromboelastography (ROTEM®), which give a rapid description of the cell-
based model of coagulation together with both cellular and humeral contributions to coagulation.  
Administration of fresh frozen plasma, platelets, cryopreciptate, factor concentrates and antifibrinolytic 
drugs can be guided by specific patterns of viscoelastic testing measurements.  At present, NICE 
guidelines currently only recommend the use of viscoelastic testing in cardiac surgery (NICE, 2014).  
However, recent meta-analysis despite showing potential to reduce the requirement of blood products 
and mortality, demonstrate that the trials of evidence these guidelines are based on are low-quality, low-
power and carry high bias (Wikkelsø et al, 2017).  Trial for guided therapy in specialty areas such as 
trauma and obstetrics are ongoing. 
 
Cell salvage 
 
If anticipated blood loss is great than 500ml or >20% of the estimated blood volume, the use of 
intraoperative cell salvage is advocated (Klein et al, 2016).  It is a commonly used technique in cardiac  
surgery but less so in other areas, for no good reason.  Cell salvage is performed with the use of a double 
lumen suction device to collect blood.  Blood is stored within a reservoir with added anticoagulants.  
Once enough blood is collected, RBCs are washed, filtered, suspended in saline and reinfused back into 
the patient.  The efficiency of cell salvage is improved with the use of antifibrinolytic drugs and the use 
of tranexamic acid (TXA) as recommended by NICE (NICE, 2015).  A Cochrane review found that the 
use of cell salvage reduced the rate of allogenic RBC transfusion by 38% (RR 0.62, 95% CI; 0.55 to 
0.70), leading to an average saving of 0.68 units of RBCs per patients (Weighted mean difference -0.68; 
95% CI; -0.88 to -0.49) (Carless et al, 2010).  In disciplines such as orthopaedic surgery, the risk 
reduction was 55%.  
Concerns have been raised surrounding the issues of re-transfused blood, and the potential harmful 
reintroduction of substances aspirated from the surgical field, including bacteria and malignant cells.  
Studies have shown that, despite the aspiration of microbiologically contaminated blood, there is no 
increase in positive cultures or postoperative infection, even though the washing phase is unable to 
eliminate all bacteria (Bowley et al, 2006; Feltracco et al, 2007).  Furthermore, a recent systematic 
review emphasising the use of leucocyte depletion filters to eliminate tumour cells should be used, and 
demonstrated no association with increased risk of tumour dissemination or metastases (Kumar et al, 
2014). European Society of Anaesthesiology guidelines suggest that the decision to use salvaged blood 
potentially contaminated with bacteria or malignant cells should be made on an individual basis (Kozek-
Langenecker et al, 2013).  Reviews focusing on outcomes relating to mortality, reoperation for bleeding, 
infection, would complication, non-fatal myocardial infarction, thrombosis, stroke and length of 
hospital stay were not increased by cell salvage (Carless et al, 2010; Meybohm et al, 2016). Up to date 
meta-analyses on randomised controlled trials focusing on washed cell salvage in all surgical groups 
demonstrated a reduced rate of infection (Meybohm et al, 2016).  
 
Antifibrinolytics 
 
Perioperative bleeding is a major indication for RBC transfusions (Levy, 2006).  To reduce blood loss 
a number of pharmacological agents are in use, which include the antifibrinolytic agents, TXA and -
aminocaproic acid (EACA).  These are synthetic lysine analogues that act to inhibit fibrinolysis by their 
action at the active sites on plasminogen, inhibiting the activation of plasmin.  Tranexamic acid should 
be used prophylactically in major surgery where perioperative blood loss is predicted to high and has 
been shown to significantly reduce perioperative blood loss.  
A significant decline in risk of death from haemorrhage with the early use of TXA in the trauma setting 
has been demonstrated.  The clinical randomisation of an antifibrinolytic in significant haemorrhage 
(CRASH-2 trial) highlighted the benefit of early therapy with TXA (1g followed by a 1-g infusion over 
8 hours), significantly reducing the risk of death from haemorrhage and all-cause mortality in traumatic 
bleeding (Collaborators CT, 2010).  This evidence has been extrapolated into other major intraoperative 
scenarios with the possibility of blood loss.  The recent ATACAS trial, demonstrated that in cardiac 
surgery patients receiving TXA there was a significantly lower risk of bleeding complications and 
transfusion requirements, also reduce reoperation compared to placebo (Myles et al, 2017).  No 
difference was observed in composite primary outcomes of mortality and thrombotic event within 30-
days of index surgery between TXA and placebo (RR 0.92; 95% CI, 0.81 to 1.05). 
Aprotinin is a potent, non-specific serine protease inhibitor, derived from bovine lung, with 
antifibrinolytic properties to directly inhibit plasmin.  It was used in cardiac procedures until it was 
withdrawn from clinic use after the blood conservation using antifibrinolytics (BART) randomised trial 
showed an increase risk of death with its use (Fergusson et al, 2008).  The results of that trial have been 
disputed and subsequently aprotinin has been re-licenced for use in myocardial revascularisation 
surgery (McMullan et al, 2013).  In terms of efficacy, the Cochrane systematic review by Henry and 
colleagues, concluded that the use of antifibrinolytics significantly reduced the requirement of 
perioperative RBC transfusion by 32%, similar for both aprotinin and TXA (Henry et al, 2011). 
 
Pillar 3 - The Postoperative period 
 
Continued effort to reduce blood loss should be ongoing into the postoperative period.  Simple 
interventions to decrease iatrogenic blood loss reduce the incidence of anaemia.  Reducing the 
frequency and volume of phlebotomy, particularly in critical care, can have an impact.  Additional 
strategies include a reduction in the sample volume with the use of paediatric blood tubes, using 
continuous sampling lines with small dead-space volumes (for arterial line samples) and evaluation of 
the requirement for each blood test according to clinical need (Raad et al, 2016).  Blood loss into drains 
is another area of interest.  In orthopaedic surgery, the use of drain has been shown to increase blood 
transfusion requirements (Parker et al, 2004).  In keeping with many enhanced recovery programmes, 
postoperative surgical drain use is decreasing.  Cell salvage can also be used after operation, with re-
transfusion of blood from drains particularly in major orthopaedic surgery (Ashworth et al, 2010).  
 
The surgical stress response, inflammation and infection may precipitate functional iron deficiency, 
similar manner to that of chronic disease.  This may contribute to the development of or further worsen 
a pre-existing IDA. This may impede recovery and rehabilitation, lead to further post-operative 
complications including readmission or re-operation.  It is unclear whether the implementation of 
restrictive transfusion practices may impact on optimal patient outcomes.  Limited research has focused 
on the area of post-operative care care, and the role of IV iron. Recent randomised controlled trials 
involving in general elective and orthopaedic surgery (Khalafallah et al, 2016) and post-gastrectomy 
(Kim et al, 2017) show that patients receiving IV iron post-operatively, had a significant increase in Hb 
values four and twelve weeks after index surgery, respectively.  Khalafallah and colleagues also showed 
a significant reduction in the requirement of blood transfusion in patients given IV iron compared to 
standard care (incidence rate ratio 0.10; 95% CI; 0.01-0.85).  This is in contrast to an earlier smaller 
study comparing IV vs. oral iron in orthopaedic surgery patients, showing no difference in blood 
transfusion requirements (Bisbe et al, 2014).  Both studies exhibit significant heterogeneity, warranting 
further larger studies in this area.   
 
Efficacy and Safety of Implementing PBM in Surgery 
 
Red blood cell transfusion is a reliable and life-saving intervention that is effective in replacing blood 
loss but in the non bleeding patient whilst it may ‘top up’ haemoglobin (Hb) levels, it does not address 
the underlying cause of the anaemia.  Increasing evidence accumulated over the past decade shows that 
transfusion is independently associated with increased morbidity, mortality, hospital and ICU length of 
stay across various surgical populations (Kotze et al, 2012; Hofmann et al, 2012; Keeler et al, 2016; 
Papageorge et al, 2017).  In addition, there are concerns surrounding increasing the risk of Transfusion 
Associated Circulatory Overload (TACO) also sepsis, and cancer recurrence in oncology patients.  The 
implementation of PBM has highlighted the best practice to restrict the use of red blood cell transfusions 
and ensure every blood transfusion is appropriate. 
Timely identification and appropriate management of preoperative anaemia as indicated in PBM 
mandates, has been shown to reduce the need for peri-operative blood transfusions, even with modest 
rises in Hb (Papageorge et al, 2017).  In a systematic review of over 20 000 patients with colorectal 
cancer, Acheson and colleagues found that 58.8% of patients received blood transfusions (Acheson et 
al, 2016).  Blood transfusion was associated with an increased all-cause mortality (OR 1.72, 95% CI; 
1.55 to 1.91; P < 0.001) and an increased OR of cancer-related mortality, combined recurrence-
metastasis-death, postoperative infection and surgical re-intervention, with a mean duration of 
observation of 62.8 (standard deviation (SD) 28.8) months in the analysed studies (Acheson et al, 2016).   
A recent Cochrane review on the impact of liberal transfusion strategies (typical transfusion trigger Hb 
90-100g/L) with more restrictive strategies (typically transfusion trigger 70-80g/L), demonstrated that 
of the 31 trials involving 12, 587 participants, no evidence of difference in patient outcomes was 
observed (Carson et al, 2016).  Many of the trials exploring the effectiveness and safety of restrictive 
transfusion practices often rely on the Hb value, regardless of whether there is active bleeding.  The 
analysed trials involve broad clinical indications, not exclusive to elective surgery, such as, critical care, 
where the indications to transfuse and what the end-goal is to achieve varies between patients.  
Additionally, it must be made aware that Hb may be an unreliable biomarker, in terms of active bleeding 
where it can remain falsely elevated in due to inadequate fluid resuscitation, or fall due to haemodilution 
intraoperatively (Klein et al, 2016).     
Although blood transfusions can be a life-saving therapy for some, each transfusion brings a small risk 
of serious reactions.  In particular, serious cardiopulmonary complications, including transfusion-
related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), which have 
both been identified as the leading cause of transfusion-associated death (Bolton-Maggs et al, 2016).  
In a recent multi-centre, retrospective analysis of almost 5000 transfusion episodes, 1.1% were 
associated with TACO, and 0.08% with TRALI (Hendrickson et al, 2016).  Other transfusion risks 
include anaphylaxis and hypotensive episodes, and milder events including febrile non-haemolytic, 
minor allergic and delayed serologic reactions.   
Conclusion 
 
Adopting PBM in surgical patients, should be paramount to reduce the risks posed by perioperative 
anaemia in red blood cell transfusions.  The programme of PBM recently addressed in national blood 
transfusion guidelines and its active implementation has demonstrated both patient and health economic 
benefits.  The decision to transfuse red blood cells should not be reflex reaction to a defined laboratory 
values, as it was often done in past practice but a considered risk-benefit decision taken on individual 
patient basis.  The principles of PBM help structure the interventions and decision relating to anaemia 
and blood transfusion, but more importantly represent a paradigm shift towards a more considered 
approach to blood transfusion, acknowledging its risks, preventatives and alternatives. 
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